Open Access System for Information Sharing

Login Library

 

Article
Cited 39 time in webofscience Cited 45 time in scopus
Metadata Downloads

Optimal induction of HPV DNA vaccine-induced CD8(+) T cell responses and therapeutic antitumor effect by antigen engineering and electroporation SCIE SCOPUS

Title
Optimal induction of HPV DNA vaccine-induced CD8(+) T cell responses and therapeutic antitumor effect by antigen engineering and electroporation
Authors
Seo, SHJin, HTPark, SHYoun, JISung, YC
Date Issued
2009-09-25
Publisher
ELSEVIER SCI LTD
Abstract
Since human papillomavirus (HPV) E6 and E7 are promising tumor antigens, we engineered E6 and E7 antigens to generate an optimal HPV DNA vaccine by codon optimization (Co), fusion of E6 and E7, addition of a tissue plasminogen activator (tpa) signal sequence, addition of CD40 ligand (CD40L) or Fms-like tyrosine kinase-3 ligand (Flt3L). The resulting constructs were investigated in terms of their antitumor activity as well as induction of HPV-specific CD8(+) T cell responses. When E6(Co) and E7(Co) were fused (E67(Co)), CD8(+) T cell responses specific for E6 or E7 antigen decreased, but the preventive antitumor effect rather improved, demonstrating the importance of broad immunity. Interestingly, Flt3L-fused HPV DNA vaccine exhibited stronger E6- and E7-specific CD8(+) T cell responses as well as therapeutic antitumor effect than that of CD40L linked HPV DNA vaccine. Finally, the optimal construct, tFE67(Co), was generated by including tpa signal sequence, Flt3L, fusion of E6 and E7. and codon optimization, which induces 23 and 25 times stronger E6- and E7-specific CD8(+) T cell responses than those of initial E67 fusion construct. In particular, inclusion of electroporation in intramuscular immunization of tFE67(Co) further enhances HPV-specific CD8(+) T cell responses, leading to complete tumor regression in a therapeutic setting. Thus, our results provide valuable insight on effective HPV DNA vaccine design and suggest that tFE67(Co) delivered with electroporation may be a promising therapeutic HPV DNA vaccine against cervical cancer. (C) 2009 Elsevier Ltd. All rights reserved.
Keywords
Broad immunity; Flt3L; Electroporation; Cervical cancer; Human papillomavirus; DNA vaccine; CD40L; IN-VIVO ELECTROPORATION; PAPILLOMAVIRUS TYPE-16 E7; MHC-CLASS-I; TUMOR-ANTIGEN; IMMUNE-RESPONSES; DENDRITIC CELLS; PROTEIN EXPRESSION; CTL RESPONSE; IMMUNOGENICITY; E6
URI
https://oasis.postech.ac.kr/handle/2014.oak/26096
DOI
10.1016/J.VACCINE.2009.07.033
ISSN
0264-410X
Article Type
Article
Citation
VACCINE, vol. 27, no. 42, page. 5906 - 5912, 2009-09-25
Files in This Item:
There are no files associated with this item.

qr_code

  • mendeley

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher

성영철SUNG, YOUNG CHUL
Dept of Life Sciences
Read more

Views & Downloads

Browse